Allegro Ophthalmics secures USD10.7m in private financing
Allegro Ophthalmics, a biotechnology company focused on the development of novel therapies to treat vitreoretinal diseases has completed a private round of equity financing for USD10.7 million. With this infusion of capital, the company is strongly positioned to reach future corporate milestones. Allegro is . The company’s lead drug candidate,
